Yes, a patient with Hepatitis C and a viral load of 30 IU/mL should be treated.
Any detectable HCV RNA level, regardless of how low, indicates active viral replication and warrants treatment. The viral load of 30 IU/mL confirms current HCV infection and meets criteria for antiviral therapy.
Why This Patient Needs Treatment
The presence of any detectable HCV RNA confirms chronic infection that will not spontaneously resolve without treatment. Modern direct-acting antiviral (DAA) regimens achieve cure rates exceeding 95% across all viral loads, and delaying treatment only allows continued liver damage, fibrosis progression, and risk of transmission 1.
The absolute viral load level does not determine treatment eligibility or urgency - what matters is that HCV RNA is detectable. Historical viral load thresholds (like 6 million IU/mL) were only used in the interferon era to guide treatment duration, not to decide whether to treat 1. These thresholds are obsolete with current DAA therapy.
Current Treatment Approach
Recommended Regimens (Pan-Genotypic)
For treatment-naïve patients without cirrhosis or with compensated cirrhosis:
- Glecaprevir/pibrentasvir: 8 weeks (no cirrhosis) or 12 weeks (compensated cirrhosis) 2, 3
- Sofosbuvir/velpatasvir: 12 weeks for all patients 1, 2
Both regimens are equally effective regardless of baseline viral load, including very low levels like 30 IU/mL.
Pretreatment Assessment Required
Before initiating therapy, determine:
- HCV genotype (though pan-genotypic regimens eliminate this as a treatment barrier)
- Fibrosis stage using FIB-4 score or transient elastography to identify cirrhosis 2
- Renal function (eGFR) - though even severe renal impairment is no longer a contraindication 4
- Medication review for potential drug-drug interactions 2
- HBsAg status to assess HBV reactivation risk 4
Monitoring
- No on-treatment laboratory monitoring required for uncomplicated cases 2, 3
- Confirm cure with HCV RNA testing 12 weeks post-treatment (SVR12) 2, 3
- For patients with advanced fibrosis/cirrhosis: continue HCC surveillance every 6 months even after cure 3
Key Clinical Pitfalls
Do not delay treatment based on low viral load. There is no minimum HCV RNA threshold for treatment - any detectable level indicates active infection requiring therapy. The 30 IU/mL level is well above the lower limit of detection of modern assays (typically 10-15 IU/mL) and unequivocally confirms active viremia 5, 6.
Do not confuse this with the historical "6 million IU/mL" threshold. That cutoff was only relevant for shortening ledipasvir/sofosbuvir treatment from 12 to 8 weeks in specific treatment-naïve, non-cirrhotic genotype 1 patients 1. It never meant patients below that threshold shouldn't be treated - quite the opposite, lower viral loads historically predicted better treatment response.
Ensure complete testing. If this patient only had HCV antibody testing without RNA confirmation, approximately one-third of cases historically had incomplete follow-up 6. The 30 IU/mL RNA result confirms current infection requiring treatment, not past resolved infection.
Special Considerations
If this patient has compensated cirrhosis, treatment is even more urgent to prevent decompensation, HCC development, and liver-related mortality 1, 4.
If severe renal impairment (eGFR <30 mL/min) is present, glecaprevir/pibrentasvir or grazoprevir/elbasvir (genotype 1b only) are preferred over sofosbuvir-based regimens 4.
For patients with decompensated cirrhosis (Child-Pugh B or C), sofosbuvir/velpatasvir with ribavirin for 12 weeks is recommended, with treatment duration and ribavirin use adjusted based on renal function 4.
The treatment decision is straightforward: detectable HCV RNA = treat now with DAAs. The era of selective treatment based on viral load, genotype, or fibrosis stage is over 1, 4, 2, 3.